RecruitingPHASE1, PHASE2NCT07150806
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Studying Meningioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Joshua Palmer
- Principal Investigator
- Joshua D Palmer, MD, MD, PHDOhio State University Comprehensive Cancer Center
- Intervention
- Actinium Ac 225 DOTATATE RYZ101(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Collaborators
RayzeBio, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07150806 on ClinicalTrials.govOther trials for Meningioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07413796Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted SuturesMedical University of Warsaw
- RECRUITINGPHASE2NCT06955169Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior TreatmentRTOG Foundation, Inc.
- RECRUITINGNANCT06831461Proton Versus Photon Radiotherapy in Adults With Primary Brain TumorsTata Memorial Centre
- RECRUITINGNCT07044076Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With MeningiomasCentre Hospitalier St Anne
- RECRUITINGPHASE2NCT05940493Abemaciclib in Newly Diagnosed Meningioma PatientsNader Sanai
- RECRUITINGNCT06874426The Impact of Endoscopic Endonasal Skull Base Surgery on OlfactionUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT06326190177Lu-DOTATATE for Recurrent MeningiomaEuropean Organisation for Research and Treatment of Cancer - EORTC
- RECRUITINGPHASE2NCT06132685Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS TrialEmory University